You may have read the new report we recently published on the orphan drug market. Rare diseases and their therapies are a huge topic to cover so inevitably, we couldn’t cover everything in the report. However, that’s what webinars are for! I’m delighted to be taking part in Evaluate’s upcoming webinar which will explore the […] The post Orphans are Getting Strategic appeared first on Evaluate.| Evaluate
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the case for why it is essential biopharma reading below. And while I have your attention, you can grab your complimentary copy of Orphan Drug Report […] The post Orphan Drug Report 2024: Slowdown a Sign of Success appeared first on Evaluate.| Evaluate
Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up. And the full webinar is available on demand. Drugs for orphan indications are a fascinating area of the pharma industry. Our recent report on the […] The post In Case You Missed It: Three Things We Learned From Our Orphan Drug Webinar appeared first on Evaluate.| Evaluate
300 million people worldwide are living with a rare disease. The “orphan” drugs created to treat them have been a fast-growing part of the pharma market for years – and their use is often high profile. Every now and then a relative niche of the pharma world hits the mainstream – orphan drugs. It happened […] The post It’s All About Impact: Why Orphan Drugs are a Big Deal for Patients and Pipelines appeared first on Evaluate.| Evaluate
Missed our webinar on orphan drugs? Catch up on the discussion with experts Melanie Senior, Puru Gaur, and Stephanie Léouzon on demand.| Evaluate